(Q44217111)

English

SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration

scientific article published in November 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration (English)

1 reference

Europe PubMed Central

30 November 2017

bioavailability

1 reference

based on heuristic

inferred from title

author name string

Simon J Tulloch

1

1 reference

Europe PubMed Central

30 November 2017

Yuxin Zhang

2

1 reference

Europe PubMed Central

30 November 2017

Angus McLean

3

1 reference

Europe PubMed Central

30 November 2017

Kathleen N Wolf

4

1 reference

Europe PubMed Central

30 November 2017

language of work or name

0 references

publication date

1 November 2002

1 reference

Europe PubMed Central

30 November 2017

Pharmacotherapy

1 reference

Europe PubMed Central

30 November 2017

22

1 reference

Europe PubMed Central

30 November 2017

11

1 reference

Europe PubMed Central

30 November 2017

1405-1415

1 reference

Europe PubMed Central

30 November 2017

Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

Stimulant medications

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

Randomized trial of a home-based family intervention for children who have deliberately poisoned themselves

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

Levoamphetamine and Dextroamphetamine: Differential Effect on Aggression and Hyperkinesis in Children and Dogs

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.16.1405.33687

21 January 2018

Identifiers

10.1592/PHCO.22.16.1405.33687

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44217111&oldid=2170791823"